急性癌症相关血栓形成患者中血小板减少症的患病率
该回顾性队列研究纳入2010至2021年间Beth Israel Deaconess Medical Center的3635例癌症相关血栓形成(CAT)成人患者,评估急性CAT合并血小板减少的患病率。实体瘤患者中血小板减少(<100 000/μL)占22%(95%CI 21%-24%),血液系统恶性肿瘤患者占47%(95%CI 43%-51%);严重血小板减少(<50 000/μL)分别占7%(95%CI 6%-8%)和30%(95%CI 27%-34%)。
要点
- 实体瘤CAT患者血小板减少(<100 000/μL)患病率为22%(95%CI 21%-24%)。
- 血液系统恶性肿瘤CAT患者血小板减少患病率为47%(95%CI 43%-51%)。
- 严重血小板减少(<50 000/μL)在实体瘤和血液肿瘤分别占7%和30%。
核心结论
- CAT与血小板减少的并发诊断非常常见,尤其在血液系统恶性肿瘤患者中。
研究设计与样本
- 回顾性队列分析,纳入2010至2021年Beth Israel Deaconess Medical Center的成人癌症患者,CAT定义为新诊断恶性肿瘤后6个月内发生急性VTE。
- 共识别3635例CAT患者,其中实体瘤80%、血液系统恶性肿瘤18%、同时合并多种癌症诊断2%。
- VTE包括急性深静脉血栓、肺栓塞、腹部或胸腔内静脉血栓及脑静脉窦血栓。
- 取索引VTE事件前后2周内最低血小板计数评估血小板减少的频率和分级。
主要发现
- 实体瘤CAT患者中血小板减少(<100 000/μL)发生率为22%(95%CI 21%-24%)。
- 血液系统恶性肿瘤CAT患者中血小板减少(<100 000/μL)发生率为47%(95%CI 43%-51%)。
- 实体瘤CAT患者中严重血小板减少(<50 000/μL)发生率为7%(95%CI 6%-8%)。
- 血液系统恶性肿瘤CAT患者中严重血小板减少(<50 000/μL)发生率为30%(95%CI 27%-34%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Venous thromboembolism (VTE) and thrombocytopenia are frequently encountered complications in patients with cancer. Although there are several studies evaluating the safety and efficacy of anticoagulation regimens in patients with cancer-associated thrombosis (CAT) with thrombocytopenia, there is a paucity of data assessing the scope of the concurrent diagnoses. This study evaluates the prevalence of thrombocytopenia among patients with acute CAT. A retrospective cohort analysis of adult patients with cancer was conducted at Beth Israel Deaconess Medical Center between 2010 and 2021 with CAT (acute VTE within 6 months after new diagnosis of malignancy). VTE included acute deep vein thrombosis, pulmonary embolism, abdominal or intrathoracic venous thrombosis, and cerebral sinus thrombosis. The lowest platelet count within 2 weeks of (before or after) the index VTE event was identified to assess the frequency and grade of concurrent thrombocytopenia. We identified 3635 patients with CAT (80% solid tumors, 18% hematologic malignancies, and 2% multiple concurrent cancer diagnoses). Thrombocytopenia (defined as platelet count <100 000/μL) occurred in 22% (95% CI 21%-24%) of patients with CAT with solid tumors diagnoses and 47% (95% CI 43%-51%) of patients with CAT and hematologic malignancies. Severe thrombocytopenia (platelet count <50 000/μL) occurred in 7% (95% CI 6%-8%) of patients with solid tumors and 30% (95% CI 27%-34%) of patients with hematologic malignancies. Concurrent diagnoses of CAT and thrombocytopenia are very common, especially among patients with hematologic malignancies.
引用
- Hsu C, Patell R, Zwicker JI, et al. The prevalence of thrombocytopenia in patients with acute cancer-associated thrombosis. Blood Adv. 2023. PMID: 36170802. doi:10.1182/bloodadvances.2022008644
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。